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The mouse macrophage-derived apoptosis inhibitor of macrophage (AIM), which is incorporated
into adipocytes and induces lipolysis by suppressing fatty acid synthase (FAS) activity, possesses
three potential N-glycosylation sites. Inactivation of N-glycosylation sites revealed that mouse
AIM contains two N-glycans in the ﬁrst and second scavenger receptor cysteine-rich domains, and
that depletion of N-glycans decreased AIM secretion from producing cells. Interestingly, the lack
of N-glycans increased AIM lipolytic activity through enhancing AIM incorporation into adipocytes.
Although human AIM contains no N-glycan, attachment of N-glycans increased AIM secretion. Thus,
the N-glycosylation plays important roles in the secretion and lipolytic function of AIM.
Structured summary of protein interactions: AIM physically interacts with FAS by anti tag coimmunopre-
cipitation (View interaction)
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The apoptosis inhibitor of macrophage (AIM, also called CD5L,
Spa, or Api6) protein is a member of the scavenger receptor cys-
teine-rich superfamily (SRCR-SF) and was initially identiﬁed as
an apoptosis inhibitor that supports the survival of macrophages
against various apoptosis-inducing stimuli [1]. As a secreted mole-
cule, AIM has been detected in human and mouse blood at varying
levels [1–6]. AIM is produced by lipid-laden foam macrophages lo-
cated within atherosclerotic plaques, and exacerbates the disease
by supporting the survival of macrophages within lesions [7]. In
addition, AIM is incorporated into mature adipocytes via CD36-
mediated endocytosis where it suppresses the activity of cytosolic
fatty acid synthase (FAS) by direct association resulting in lipolysis,
the degradation of triacylglycerols into glycerol and free fatty acidschemical Societies. Published by E
hage; SRCR, scavenger recep-
toll-like receptor; FAS, fatty
ukin-6; Saa-3, serum amyloid
hine
esearch Program, Mitsubishi
oundation for Research on
dation (to S.A.).
unkyo-ku, Tokyo 113-0033,(FFA) [8,9]. In obesity, the augmentation of blood AIM levels in-
duces vigorous lipolysis in adipose tissues, increasing local extra-
cellular fatty acid concentrations to a level sufﬁcient for the
stimulation of adipocyte-expressing toll-like receptor (TLR) 4,
which triggers macrophage recruitment and chemokine produc-
tion by adipocytes [10]. This response causes chronic, low-grade
inﬂammation in adipose tissues, which is associated with insu-
lin-resistance, and thus contributes to the development of multiple
obesity-induced metabolic and cardiovascular diseases [8–11].
Both murine and human AIM (hAIM) possess several putative
N-glycosylation sites (asparagine-X-threonine or serine; N-X-S/T,
X – P). However, the precise contribution of the N-glycans to the
AIM function and/or other protein characteristics of AIM remain
unsolved. Therefore, in this study, we investigated the effects of
glycomodiﬁcation on AIM function, focusing on its lipolytic effect,
by generating variant AIM proteins with reduced or additional
N-glycans from site-directed mutagenesis.
2. Materials and methods
2.1. Digestion of glycans
Deglycosylation was performed using Enzymatic Protein Degly-
cosylation Kit (Sigma, USA). Each type of AIM was produced in the
culture supernatant of HEK293T cells and immune-precipitated
with anti-HA antibody (Roche, Germany). The precipitates werelsevier B.V. All rights reserved.
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PNGase F at 37 C for 48 h. Endogenous AIM from mouse serum
was immune-precipitated with anti-AIM antibody (rat, #12) and
reacted with PNGase F in the presence of SDS and Triton X-100.
For digestion of O-glycans, mixture of endo-O-glycosidase, a-2
(3,6,8,9)-neuraminidase, b-1,4-galactosidase, and b-N-acetylgluco-
saminidase as well as PNGase F was used.
2.2. Lectin blot
Five micrograms of puriﬁed AIM were used for SDS–PAGE and
transferred on PVDF membrane. After blocking with 5% BSA-TBST,
20 lg/ml lectins were applied. Binding was detected with strepta-
vidin-HRP. Normal mouse immunoglobulin G (Sigma) was used as
a positive control.
2.3. FITC-labeling of AIM and uptake experiment
Puriﬁed AIM was labeled with FITC by using SureLINKTM Fluo-
rescein (FITC) Labeling Kit (KPL, USA). Labeling efﬁciency was eval-
uated by measurement of absorbance at 280 nm (for protein
concentration) and 490 nm (for ﬂuorescein), conﬁrming no differ-
ence between WT and DS1DS2 mAIM. At day 7 of adipocyte differ-
entiation, 3T3-L1 cells were treated with various concentrations of
FITC-AIM for 6 h. Cells were lysed in lysis buffer containing 1% NP-
40 and 150 mM Tris–HCl (pH 7.5) after thoroughly washing with
PBS. Uptake of FITC-AIM into 3T3-L1 adipocytes was quantiﬁed
by measurement of 535 nm ﬂuorescence. Values were normalized
by protein concentration in the lysates.
2.4. Statistic
All statistical analyses were performed using the two-tailed
Student’s t-test. ⁄: P < 0.05, ⁄⁄: P < 0.01, ⁄⁄⁄: P < 0.001.
Descriptions for Reagents and antibodies, Procedures for Vector
Construction, Puriﬁcation of recombinant AIM, Lipolysis assay,
Quantitative RT-PCR and primer sequences, and Co-immuno-pre-
cipitation assay, appear in Supplementary Materials and methods.
3. Results
3.1. Analysis of N-glycosylated sites in AIM
Since murine AIM (mAIM) has a larger molecular weight
(55 kDa) than predicted from its amino acid sequence (39 kDa),
it is possible that mAIM is naturally glycosylated. The C57BL/6
(B6) strain mAIM amino acid sequence (NCBI: NP_033820) sug-
gests that each of three SRCR domain possesses a potential N-gly-
cosylation site; i.e. the asparagine (N) 99, N229, and N316 residues,
respectively (Fig. 1A). Although we also found that the FVB/N and
BALB/c mouse strains have a fourth N-glycosylation site at the
N195 residue of AIM (GenBank: AAH94459 and AF018268.1,
respectively), we used the B6-type AIM as wild-type (WT) in the
present study. To verify the presence of N-glycans at each potential
site, we generated three variant AIM recombinant proteins each
containing a single N-glycosylation site in a different SRCR domain
using combinational amino acid modiﬁcations of asparagine to
glutamine at N99 (SRCR1), N229 (SRCR2), and N316 (SRCR3), and
a fourth variant lacking an N-glycosylation site. Thus, variants
DS2DS3, DS1DS3, DS1DS2, and DS1DS2DS3 harbor N-glycosyla-
tion sites in SRCR1, 2, 3, or none of the SRCR domains, respectively.
WT and variant mAIM proteins with an HA-tag at the C-termi-
nal were produced in HEK293T cells, immunoprecipitated using an
anti-HA antibody, and the precipitates were treated with the pro-
tein N-glycosidase F (PNGase F) under non-denaturing conditions.
PNGase F treatment reduced the WT molecular weight to that ofDS1DS2 and DS1DS2DS3, which were of identical size (Fig. 1B).
DS2DS3 and DS1DS3 were intermediate in size between WT and
DS1DS2DS3, which was reduced to that of DS1DS2DS3 after PNG-
ase F treatment (Fig. 1B). These results suggest that WT mAIM pos-
sesses N-glycans at the SRCR1 and SRCR2 domains, and that the
N316 in SRCR3 lacks an N-glycan.
We also attempted PNGase F treatment of endogenous mAIM
after precipitating AIM frommouse serumusing an anti-mAIManti-
body. The molecular weight of endogenous AIM was identical to
that of WT recombinant mAIM, but reduced to that ofDS1DS2 after
PNGase F treatment, as assessed by immunoblotting under reducing
conditions (Fig. 1C), clearly suggesting that the endogenous blood
mAIM possesses N-glycans like as seen in recombinant mAIM.
The hAIM has a smaller molecular weight compared with
mAIM, although their predicted sizes from amino acid sequences
are similar (38 kDa). The hAIM amino acid sequence (NCBI:
NP_005885) indicates the presence of a potential N-glycosylation
site (asparagine-X-cysteine; NXC) [12,13] in the SRCR2 and SRCR3
domains. It was reported that the NXC motif might have the poten-
tial to attach N-glycans, though it is not a consensus site like mAIM
N-X-T/S. However, PNGase F treatment did not reduce the molec-
ular size of WT hAIM, suggesting no N-glycosylation at these
NXC sites (Fig. 1D). This result is consistent with a previous obser-
vation by Gebe et al. suggesting that hAIM might not contain puta-
tive N-glycosylation [2].
3.2. Glycomodiﬁcation proﬁling in AIM
To determine the patterns of carbohydrate chains in WT and
variant AIM proteins, we employed ﬁve different lectins which rec-
ognize variable motifs of the sugar attachment. As shown in Fig. 1E,
concanavalin A (Con A), which recognizes all types of branched N-
glycans, recognized WT, DS1, and DS2, but not DS1DS2 mAIM. The
Sambucus nigra agglutinin (SNA), but not the Maackia amurensis
agglutinin (MAA), reacted with WT mAIM, suggesting that the
two mAIM N-glycans possess a2,6- but not a2,3-linked sialic acids.
Although the Ulex europaeus agglutinin (UEA-I) detected no termi-
nal fucose in WT mAIM, the Erythrina cristagalli agglutinin (ECA)
blot revealed the presence of terminal N-acetylgalactosamine in
the second mAIM N-glycan at N229 (SRCR2). This suggests that
the N-glycan at N99 (SRCR1) possesses only a2,6-sialylated termi-
nals, and the one at N299 (SRCR2) possesses both a2,6-sialylated
and non-sialylated terminals.
Since any mutation in the amino acid sequence may affect the
receptiveness of O-linked glycosylation, we also evaluated the state
of O-glycosylation in WT and variant AIM proteins by treating
them with three different exoglycosidases and one endoglycosi-
dase. No O-glycan was detected in either mAIM or hAIM (Supple-
mentary Fig. 1A). According to the online database (NetOGlyc 3.1
Server, http://www.cbs.dtu.dk/services/NetOGlyc/), there are four
potential O-glycosylation sites located at serine (S)123, S129,
S130, and S132 within the hinge-region linking SRCR1 and SRCR2
domains of hAIM. However, their potentiality scores are only
around 0.38, which is below the threshold of 0.50. To further test
the presence of O-glycosylation in hAIM, we generated a variant
hAIM protein harboring a substitution of alanine for serine at all
of these potential sites. The size of this variant hAIM (D4O) was
similar to that of WT hAIM protein, implying no prominent O-gly-
cosylation in hAIM (Supplementary Fig. 1B).
3.3. N-glycosylation increases AIM secretion
We next investigated the inﬂuence of different glycomodiﬁca-
tions on the functional characteristics of AIM. We ﬁrst tested the
secretion of variant AIM proteins (DS1 and DS2, possessing a sin-
gle N-glycan at SRCR2 and SRCR1, respectively, and DS1DS2 with
Fig. 1. Detection of N-glycosylated sites in murine and human AIMs by PNGase F treatment. (A) the potential N-glycosylation sites (NXS/T) are shown along the murine and
human AIM amino acid sequences. Sg: signal sequence. Filled branch, N-glycans detected by PNGase F treatment. Gray branch, N-glycan detected only in FVB/N and BALB/c
strains, not in C57BL/6 strain. Open branch, potential N-glycosylation but not detected by PNGase F treatment. (B) analysis of N-glycosylation in mAIM variants. Deletion of
each of the three potential sites is designated DS1, DS2, and DS3. Each mAIM variant protein tagged with an HA peptide was immunoprecipitated using an anti-HA antibody
from HEK293T cell culture supernatants. The molecular weight of digested mAIM variants was assessed by immunoblotting. A representative result of three independent
experiments is shown. (C) serum from WT or AIM/ mice was immunoprecipitated using an anti-AIM monoclonal antibody. Under SDS denaturing conditions, the
precipitates were treated with PNGase F. The molecular weight of the AIM protein with and without PNGase F-treatment was determined by immunoblotting using the rabbit
polyclonal antibody to mouse and human AIM (Rab2). Recombinant mAIM variants were used as size references. (D) analysis of hAIM N-glycosylation. The molecular weight
of hAIM-HA recombinant protein produced by HEK293T cells with or without PNGase F-treatment was assessed by immunoblotting using an anti-HA antibody. A
representative result of three different experiments is shown. (E) the structural proﬁles of N-glycans for WT and variant mAIM as well as hAIM proteins were analyzed by
blotting with different types of lectins. Con A detects branched N-glycans; SNA detects a2,6-linked sialic acids; MAA detects a2,3-linked sialic acids; UEA-I detects terminal
fucose residues; and ECA detects terminal galactose b1,4-N-acetylgalactosamine. The lane with a speciﬁc positive signal is indicated by asterisk. Normal mouse IgG was used
as a positive control for N-glycosylation.
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iant and WT mAIM tagged with HA were transfected to HEK293T
cells, and secretion was evaluated by immunoblotting using
supernatants and cell lysates. As shown in Fig. 2, deprivation of
both N-glycans in mAIM (DS1DS2) dramatically decreased the
secretion efﬁciency. Moreover, DS1 and DS2 mAIMs showed
intermediate secretion efﬁciency between WT and DS1DS2
(Fig. 2). These results suggest that each N-glycan independently
increases the secretion of mAIM protein. Indeed, it is known that,
for some glycoproteins, N-glycans are essential modules to exit
the secretory pathway [14–16]. Note that HEK293T cells did not
express CD36 (Supplementary Fig. 2A). In addition, we treated
HEK293T cells with WT or DS1DS2 mAIM protein (100 lg/ml)
for 6 h, and addressed whether the cells incorporated the added
AIM protein by immunoblotting using the culture supernatants
and cell lysates. As shown in Supplementary Fig. 2B, no decrease
of AIM proteins in the supernatant or no increase of AIM signal in
cell lysate after the 6 h incubation was detected. Moreover, ﬂuo-
rescein isothiocyanate-labeled AIM was not detected in the lysate
of HEK293T cells (Supplementary Fig. 2C). These results indicate
that HEK293T cells did not incorporate WT or variant AIM pro-
tein, and that our results in Fig. 2 precisely represent secretion
efﬁciency of AIM proteins.3.4. Lack of N-glycosylation increases the AIM lipolytic function
To determine whether N-glycosylation variation might inﬂu-
ence the lipolytic function of AIM, we performed in vitro lipolysis
analysis of 3T3-L1 adipocytes using DS1, DS2, or DS1DS2 mAIM
puriﬁed proteins. On day 7 after maturation induction by insulin,
dexamethasone (DEX), and 3-isobutyl-1-methylxanthine (IBMX),
cells were challenged with each variant AIM protein (50 lg/ml)
for two days, and the various outputs of lipolysis were assessed.
As shown in Fig. 3A, the downregulation of lipid droplet-coating
proteins including Fat speciﬁc protein 27 (Fsp27) and Perilipin, a
hallmark of AIM-induced lipolysis [9,10], was induced more by
DS1DS2 than DS1, DS2, or WT mAIM.
The lipolytic response efﬂuxes FFAs from adipocytes, which sec-
ondarily induce the mRNA expression of inﬂammatory genes such
as Interleukin-6 (IL-6) and Serum amyloid A-3 (Saa-3) through stim-
ulation of TLR4 expressed by adipocytes [9,10]. The increased
expression of these inﬂammatory genes was also observed in
3T3-L1 adipocytes challenged with the DS1DS2 variant (Fig. 3B).
Such advanced lipolysis was also conﬁrmed by the observed
remarkable shrinkage of lipid droplets after treatment with
DS1DS2 when cells were stained with oil red O (Fig. 3C). In
addition, DS1DS2 induced more prominent glycerol efﬂux from
Fig. 2. Effects of N-glycosylation on mAIM secretion. Left: DS1, DS2, DS1DS2, or WT mAIM-HA proteins were transiently produced by HEK293T cells, and the amount of each
protein in the supernatant vs. that in the cell lysate was comparatively analyzed by immunoblotting using an anti-HA antibody. Right: the ratio (supernatant:lysate) was
calculated after quantiﬁcation of signals using NIH ImageJ software, and presented after normalizing to that of WT mAIM.
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glycans augments the lipolytic function of AIM.
3.5. How the lack of N-glycans increases mAIM lipolytic activity
AIM is incorporated into adipocytes via CD36-mediated endocy-
tosis and directly associates with cytosolic FAS, reducing its enzy-
matic activity and leading to lipolysis [10]. Therefore, to
understand how the lack of N-glycans increases mAIM lipolytic
activity, we evaluated the incorporation and FAS binding efﬁciency
in WT and DS1DS2 mAIM. First, to test incorporation, 3T3-L1 adi-
pocytes were treated for 6 h at 37 C with WT or DS1DS2 mAIM
chemically conjugated with FITC, harvested, and evaluated for
intracellular ﬂuorescence. As shown in Fig. 4A, increased FITC
incorporation was observed for DS1DS2 mAIM compared to WT.
By contrast, co-immunoprecipitation of HA-tagged WT or DS1DS2
mAIM with FLAG-tagged FAS expressed in HEK293T cells revealed
similar binding levels of WT and DS1DS2 to FAS (Fig. 4B). DS1 and
DS2 also showed a similar binding level to FAS. Thus, the advanced
lipolysis caused by the lack of N-glycans appears to be brought
about by increased AIM endocytosis, and not by inﬂuencing FAS
binding efﬁciency.
3.6. Effects of gained N-glycans in hAIM
As N-glycosylation at even a single site appears to decrease AIM
lipolytic activity then increase AIM secretion, we introduced an
artiﬁcial N-glycosylation site into hAIM, which lacks an endoge-
nous N-glycan. The site was added by substituting asparagine for
threonine 97 in the SRCR1 domain, resulting in an identical N-gly-
cosylation site to that in mAIM SRCR1. Attachment of the addi-
tional N-glycan was conﬁrmed by Con-A blotting (Supplementary
Fig. 3A). We next compared its secretion and lipolytic activity with
those of WT hAIM. As expected, the +S1 exhibited a threefold in-
crease in secretion efﬁciency compared to WT (Supplementary
Fig. 3B). Whilst, the secretion efﬁciency of theD4O variant of hAIM,
which lacks all potential O-glycosylation sites in hAIM (Supple-
mentary Fig. 1B), was comparable to that of WT hAIM (Supplemen-
tary Fig. 3B). Interestingly, unlike mAIM, the hAIM lipolytic
function was not affected by adding an N-glycan, as treatment of
3T3-L1 adipocytes with WT or +S1 reduced Fsp27 and Perilipin
mRNA and increased IL-6 and Saa-3 mRNA to similar levels (Sup-
plementary Fig. 3C, D). This was also supported by the similar state
of lipid droplets assessed by Oil red O staining (SupplementaryFig. 3E) and the comparable glycerol efﬂux (Supplementary
Fig. 3F) in 3T3-L1 adipocytes challenged with WT or +S1 hAIM.
4. Discussion
Our approach to modify the glycosylation of AIM ﬁrstly entailed
the proﬁling of natural glycomodiﬁcation on the AIM protein. We
constructed AIM variants that lacked potential N-glycosylation
sites in different combinations. Natural N-glycosylation at S1 and
S2 sites was detected by PNGase F treatment of these variants
(Fig. 1). According to glycoproteomic analysis using liquid chroma-
tography–mass spectrometry (LC–MS/MS), N-glycans are attached
to N99 and N229 of murine AIM [17], consistent with our current
results. The reason why the third site N316 is not N-glycosylated is
that it is too proximal to the C-terminal of AIM to be reached by
oligosaccharyltransferases located in the endoplasmic reticulum
(ER) lumen [18].
Our PNGase F assay detected no N-glycosylation in hAIM,
although the molecular sizes of hAIM and mAIM after PNGase F
treatment were higher than their predicted ones, indicating the
presence of other modiﬁcations such as O-glycosylation. However,
our enzymatic method detected no O-glycans, although the pres-
ence of small or atypical O-glycan structures cannot be ruled out.
hAIM from a different cell type (HEK293-EBNA) was shown to be
sialylated [19], and it is also possible that AIM possesses other
post-transcriptional modiﬁcations. Alternatively, the 11 disulﬁde
bonds present in the three SRCR domains in both human and
mouse AIM might structurally interfere with enzyme access for
deglycosylation of O-glycans, resulting in their incomplete deple-
tion. Further studies are required to clarify the complete character-
istics of carbohydrate chains associated with AIM.
Our results demonstrate that null depletion of N-glycan signiﬁ-
cantly augments the lipolytic function of mAIM (Fig. 3). This
enhancement appears to result from mainly increased levels of
endocytosis mediated by the cell surface scavenger receptor
CD36 (Fig. 4). However, this is not consistent with a previous re-
port showing that CD36 expressed on 3T3-L1 adipocytes recog-
nizes advanced glycation end (AGE) products [20–22]. It is
possible that the recognition by CD36 might differ in conventional
branched N-glycans and non-structural glycation. Alternatively, a
high afﬁnity for CD36 because of excess carbohydrates in AIM
might allow a higher rate of endocytic degradation [21]. In addi-
tion, we found that an N-glycan attachment to hAIM had no signif-
icant effect on its lipolytic function (Supplementary Fig. 3). It might
Fig. 3. Lipolytic function of mAIM variants. Differentiated 3T3-L1 adipocytes (day 6) were challenged with the indicated AIM variant protein (50 lg/ml) for two days, and
lipolysis was evaluated using different parameters. QPCR analysis of the mRNA levels of (A) Fsp27 and Perilipin, lipid droplet-coating proteins, and (B) Il-6 and Saa-3,
inﬂammatory proteins. Values were normalized to the mRNA levels of b-actin. Data represent averages ± SEM from three different experiments. Lower panel shows the dose-
dependent effect of mAIM variants on Fsp27 mRNA levels. Data are relative to that in cells with no treatment with any type of mAIM variant. (C) representative result of Oil
red O staining. Bars: 100 lm. (D) glycerol efﬂux. For this experiment, overnight serum-deprived adipocytes (day 7) were incubated in serum-free DMEM in the presence of
AIM variant proteins (40 lg/ml) for 24 h. After the incubation, supernatant was collected, and glycerol contents were measured using a glycerol assay kit (Bio Vision Inc.).
Fig. 4. Uptake by adipocytes but not binding to FAS makes differences between WT and DS1DS2 mAIM. (A) differentiated 3T3-L1 adipocytes (day 7) were challenged with
FITC-labeled WT or DS1DS2 mAIM at the indicated concentration, and mAIM incorporation was assessed by measurement of 535 nm ﬂuorescence in cellular lysates. n = 3 for
each plot. Error bars: SEM. (B) indicated HA-tagged mAIM variants and FLAG-tagged mouse FAS were produced in HEK293T cells from which mAIM variant protein was
immunoprecipitated using an anti-HA antibody. Precipitates were immunoblotted using an anti-FLAG antibody to detect FAS co-precipitation. Immunoblotting of cell lysates
for mAIM variant-HA and FLAG-mFAS is also shown. FAS protein was co-immunoprecipitated with any type of mAIM-variant at a similar level.
M. Mori et al. / FEBS Letters 586 (2012) 3569–3574 3573
3574 M. Mori et al. / FEBS Letters 586 (2012) 3569–3574be possible that adding only one N-glycan instead of two (at SRCR 1
and 2) to hAIM did not decrease the lipolytic function. Overall, fur-
ther experiments to assess the afﬁnity of AIM variants for CD36 are
necessary to fully understand this.
In summary, we presented that the state of N-glycosylation pro-
foundly affects the secretion efﬁciency and lipolytic function of
AIM. Establishment of modiﬁed AIM with better production and
activity through glycoengineering might contribute to the develop-
ment of next-generation therapy against obesity and obesity-asso-
ciated metabolic disorders.
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